The estimated Net Worth of Dinesh V Ph D Patel is at least $30.7 Million dollars as of 7 June 2024. Dinesh Patel owns over 35,000 units of Protagonist Therapeutics Inc stock worth over $23,085,438 and over the last 8 years he sold PTGX stock worth over $5,684,786. In addition, he makes $1,948,340 as President, Chief Executive Officer, and Director at Protagonist Therapeutics Inc.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
Dinesh Patel PTGX stock SEC Form 4 insiders trading
Dinesh has made over 28 trades of the Protagonist Therapeutics Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he sold 35,000 units of PTGX stock worth $1,231,650 on 7 June 2024.
The largest trade he's ever made was selling 75,000 units of Protagonist Therapeutics Inc stock on 13 December 2023 worth over $1,506,000. On average, Dinesh trades about 13,245 units every 62 days since 2016. As of 7 June 2024 he still owns at least 515,415 units of Protagonist Therapeutics Inc stock.
You can see the complete history of Dinesh Patel stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Dinesh Patel biography
Dr. Dinesh V. Patel Ph.D. serves as President, Chief Executive Officer, Director of the Company. Dr. Patel has served as a member of the Company's Board and as the Company's President and Chief Executive Officer since December 2008. Dr. Patel has more than 35 years of executive, entrepreneurial and scientific experience spanning the pharmaceutical, biotechnology and biopharmaceutical industries. Prior to joining the Company, Dr. Patel served from 2006 to 2008 as the President and Chief Executive Officer of Arête Therapeutics, a privately held company focused on the development of novel drugs for metabolic syndrome. Prior to that, he was President, Chief Executive Officer and Co-Founder of Miikana Therapeutics, an oncology-based company, from 2003 until it was acquired by Entremed (later renamed CASI Pharmaceuticals) in 2005. Prior to Miikana, Dr. Patel held positions of increasing responsibility at Versicor (later renamed Vicuron and which was acquired by Pfizer in 2005), from 1996 to 2003, most recently as Senior Vice President of Drug Discovery and Licensing. Prior to Vicuron, Dr. Patel was a director of chemistry at the combinatorial chemistry company Affymax, from 1993 to 1996. Dr. Patel was a medicinal chemist at BristolMyers Squibb from 1985 to 1993. Dr. Patel received his Ph.D. in Chemistry from Rutgers University, New Jersey and his B.S. in Industrial Chemistry from S. P. University, Vallabh Vidyanagar, India. The Company believes that because of his expertise, extensive knowledge of the Company and experience as an executive officer of biotechnology companies, Dr. Patel is able to make valuable contributions to the Board.
What is the salary of Dinesh Patel?
As the President, Chief Executive Officer, and Director of Protagonist Therapeutics Inc, the total compensation of Dinesh Patel at Protagonist Therapeutics Inc is $1,948,340. There are no executives at Protagonist Therapeutics Inc getting paid more.
How old is Dinesh Patel?
Dinesh Patel is 63, he's been the President, Chief Executive Officer, and Director of Protagonist Therapeutics Inc since 2019. There are 7 older and 10 younger executives at Protagonist Therapeutics Inc. The oldest executive at Protagonist Therapeutics Inc is Dr. David Y. Liu, 71, who is the Chief Scientific Officer and Head of Discovery & Pre-Clinical Devel..
What's Dinesh Patel's mailing address?
Dinesh's mailing address filed with the SEC is C/O PROTAGONIST THERAPEUTICS, INC., 7707 GATEWAY BLVD., SUITE 140, NEWARK, CA, 94560-1160.
Insiders trading at Protagonist Therapeutics Inc
Over the last 8 years, insiders at Protagonist Therapeutics Inc have traded over $11,629,969 worth of Protagonist Therapeutics Inc stock and bought 3,007,840 units worth $35,519,073 . The most active insiders traders include Capital Partners Gp, L.L.C...., & Johnson Johnson & Johnson..., and X L.P.Canaan Partners X Llc.... On average, Protagonist Therapeutics Inc executives and independent directors trade stock every 37 days with the average trade being worth of $2,387,307. The most recent stock trade was executed by William D. Waddill on 24 July 2024, trading 8,000 units of PTGX stock currently worth $103,040.
What does Protagonist Therapeutics Inc do?
protagonist therapeutics is a clinical-stage biopharmaceutical company with a proprietary technology platform which is utilized to discover and develop novel peptide-based drugs to address significant unmet medical needs. its primary focus is on developing potential first-in-class oral targeted therapy-based peptide drugs that work by blocking biological pathways that are currently targeted by marketed injectable antibody drugs. protagonist's initial lead peptide product candidates, ptg-100 and ptg-200, are based on this approach, and the company believes these candidates have the potential to transform the existing treatment paradigm for inflammatory bowel disease (ibd), consisting primarily of ulcerative colitis and crohn's disease. ptg-100, a potential first-in-class oral peptide alpha-4-beta-7 integrin antagonist, is currently in a global phase 2b clinical trial for treatment of moderate-to-severe ulcerative colitis. ptg-200, a first-in-class oral interleukin-23 receptor antagonist
What does Protagonist Therapeutics Inc's logo look like?
Complete history of Dinesh Patel stock trades at Protagonist Therapeutics Inc
Protagonist Therapeutics Inc executives and stock owners
Protagonist Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Dinesh Patel,
President, Chief Executive Officer, Director -
Suneel Gupta,
Chief Development Officer -
David Liu,
Chief Scientific Officer, Head of Research & Development -
Dr. Dinesh V. Patel Ph.D.,
CEO, Pres, Interim PAO, Sec. & Director -
Dr. David Y. Liu,
Chief Scientific Officer and Head of Discovery & Pre-Clinical Devel. -
Dr. Suneel K. Gupta Ph.D.,
Chief Devel. Officer -
Harold Selick,
Independent Chairman of the Board -
William Waddill,
Independent Director -
Bryan Giraudo,
Independent Director -
Sarah Noonberg,
Independent Director -
Lewis Williams,
Independent Director -
Sarah O'Dowd,
Independent Director -
Brian Korb,
IR Contact Officer -
Samuel Saks,
Chief Medical Officer -
Donald Kalkofen,
Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer -
Asif Ali,
Exec. VP & Chief Financial Officer -
Dr. Scott Eric Plevy M.D.,
Exec. VP and Therapeutic Head of Gastroenterology -
Dr. Ashok Bhandari Ph.D.,
Sr. VP of Discovery Chemistry & Process Research -
Mohammad Masjedizadeh,
Exec. VP & CTO -
Donald A. Kalkofen,
Chief Financial Officer -
Dr. Larry Mattheakis,
Sr. VP of Discovery Biology & Translational Research -
Dr. Ashok Bhandari,
Sr. VP of Discovery Chemistry & Process Research -
Carena Spivey,
Exec. Director of HR -
Matthew M. Gosling,
Exec. VP & Gen. Counsel -
Dr. Mark Smythe,
Founder & VP Technology -
Dr. Richard S. Shames,
Clinical Advisor -
Arturo Md Molina,
Chief Medical Officer -
Armen Shanafelt,
Director -
Chaitan Phd Khosla,
Director -
Julie Papanek,
Director -
Richard S. Shames,
Chief Medical Officer -
Thomas P. O'neil,
Chief Financial Officer -
William A Hodder,
Sr. VP - Corporate Development -
& Johnson Johnson & Johnson...,
-
X L.P.Canaan Partners X Llc...,
-
Management Group, Llc Lilly...,
-
Asif Ali,
Chief Financial Officer -
Capital Partners Gp, L.L.C....,
-
Daniel N Jr Swisher,
Director